Average Upfront Payments in Clinical-Stage Biotech Deals
This month, we revisit upfront payments in clinical-stage biotech deals, breaking out the average payments by equity and cash.
You may also be interested in...
Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.
Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.